China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 8 January 2025 ...

The most common types include Alzheimer’s disease, vascular dementia, Lewy body dementia, frontotemporal dementia and mixed dementia, according to Dementia UK. Lead-charity Alzheimer's society have ...

This offers the potential for targeted drug therapy of clinically symptomatic visual hallucinations in patients with schizophrenia using acetylcholinesterase inhibition. Methods: A systematic ...

This article looks at the rationale behind the combined use of acetylcholinesterase inhibitors and the N-methyl-D-aspartate-receptor antagonist, memantine, from both preclinical and clinical ...

Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China ...

Insilico Medicine Shanghai Ltd, Suite 901, Tower C, Changtai Plaza, 2889 Jinke Road, Pudong New District, Shanghai 201203, China ...

ZUNVEYL is a next generation acetylcholinesterase inhibitor approved in the US for the treatment of mild-to-moderate Alzheimer’s disease. Terms of the agreement total $44 million, which includes ...

Zunveyl is a next-generation acetylcholinesterase inhibitor approved in the U.S. for mild-to-moderate Alzheimer's disease. The deal value is $44 million, including $6 million in total upfront ...

ZUNVEYL was approved in July 2024 by the U.S. FDA. As a new generation of acetylcholinesterase inhibitor (AChEI), ZUNVEYL can inhibit the acetylcholinesterase from breaking down the neurotransmitter ...